Valneva SE INRLF

INRLF Company Overview

Valneva SE is a specialty vaccine company focused on the development, manufacture, and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical needs. The company operates primarily within the biotechnology and vaccine industries, with commercial and clinical-stage programs targeting travel vaccines, vector-borne diseases, and other infectious disease indications. Valneva generates revenue through product sales, collaboration agreements, licensing arrangements, and government-supported vaccine supply contracts.

The company’s primary commercial products include vaccines for Japanese encephalitis, cholera and travelers’ diarrhea prevention, and chikungunya. Its business model combines internally developed vaccine platforms with strategic collaborations involving larger pharmaceutical companies and government agencies. Valneva traces its origins to the merger of Intercell AG of Austria and Vivalis SA of France in 2013, creating a European vaccine-focused biotechnology company with integrated research, development, manufacturing, and commercial operations. The company has positioned itself as a niche vaccine developer with expertise in inactivated vaccines and adjuvant technologies.